scholarly journals Why radiography should no longer be considered a surrogate outcome measure for longitudinal assessment of cartilage in knee osteoarthritis

2011 ◽  
Vol 13 (6) ◽  
pp. 247 ◽  
Author(s):  
Ali Guermazi ◽  
Frank W Roemer ◽  
Deborah Burstein ◽  
Daichi Hayashi
Keyword(s):  
Knee Osteoarthritis ◽  
Outcome Measure ◽  
Longitudinal Assessment ◽  
Surrogate Outcome ◽  
Surrogate Outcome Measure

Abstract 353: Performance of SOFA Score to Predict Mortality at Hospital Discharge After Cardiac Arrest

Circulation ◽  
2018 ◽  
Vol 138 (Suppl_2) ◽  
Author(s):  
Anne V Grossestreuer ◽  
Tuyen Yankama ◽  
Ari Moskowitz ◽  
Anthony Mahoney-Pacheco ◽  
Varun Konanki ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Hospital Discharge ◽  
Sofa Score ◽  
Statistical Power ◽  
Goodness Of Fit ◽  
Outcome Measure ◽  
Model Performance ◽  
Surrogate Outcome ◽  
Surrogate Outcome Measure ◽  
Good Calibration

Introduction: Cardiac arrest (CA) outcomes, when dichotomized as survival/non-survival, limit statistical power of interventional studies and do not acknowledge hospital-level factors independent of post-CA sequelae. We explored the Sequential Organ Failure Assessment (SOFA) score at 72 hours post-CA as a surrogate outcome measure for mortality. We also assessed methods to account for death <72 hours post-CA in SOFA score computation. Methods: This was a single center retrospective study of post-CA patients from 1/08-12/17. SOFA score components were abstracted at baseline, 24, 48, and 72h post-CA. Thirteen ways of accounting for missing data were assessed. The outcome was mortality at hospital discharge. Model performance was assessed using area under the receiver-operator characteristic (AUC) curves and Hosmer-Lemeshow goodness of fit statistics. Results: Of 847 patients, 528 (62%) had complete baseline SOFA scores and 205 (24%) had complete scores at 72h. Death <72h occurred in 28%; 45% survived to hospital discharge. SOFA score at 72h without accounting for death had an AUC of 0.62. The best performing SOFA model at 72h with good calibration imputed a 20% increase over the last observed SOFA score in patients who expired <72h with an AUC of 0.79 (95% CI: 0.74-0.83). In terms of change in SOFA at 72h from baseline, the best performing model with good calibration imputed death <72h as the highest possible score (AUC: 0.88 [95% CI: 0.84-0.92]). These results were consistent when analyzing in- and out-of-hospital CA separately, although the change from baseline model was not well calibrated in in-hospital arrests. Conclusions: Without consideration of death, SOFA scores at 72 hours post-CA perform poorly. Imputing for early mortality improved the model. If this imputation structure is validated prospectively, SOFA could provide a scoring system to predict death at hospital discharge and serve as a surrogate outcome measure in interventional studies.

scholarly journals Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer

2018 ◽  
Vol 5 (01) ◽  
pp. 1 ◽  
Author(s):  
Matthew S. Brown ◽  
Grace Hyun J. Kim ◽  
Gregory H. Chu ◽  
Bharath Ramakrishna ◽  
Martin Allen-Auerbach ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Bone Scan ◽  
Metastatic Prostate Cancer ◽  
Outcome Measure ◽  
Lesion Area ◽  
Surrogate Outcome ◽  
Surrogate Outcome Measure

Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 11521-11521 ◽  
Author(s):  
John Marshall ◽  
Lee Steven Schwartzberg ◽  
Gerold Bepler ◽  
David Spetzler ◽  
Wafik S. El-Deiry ◽  
...  
Keyword(s):  
Outcome Measure ◽  
Surrogate Outcome ◽  
Surrogate Outcome Measure

Serum Urate as a Proposed Surrogate Outcome Measure in Gout Trials: From the OMERACT Working Group.

2021 ◽  
Author(s):  
Melanie Birger Morillon ◽  
Robin Christensen ◽  
Jasvinder A. Singh ◽  
Nicola Dalbeth ◽  
Kenneth Saag ◽  
...  
Keyword(s):  
Working Group ◽  
Outcome Measure ◽  
Serum Urate ◽  
Surrogate Outcome ◽  
Surrogate Outcome Measure

scholarly journals Silent brain infarcts on diffusion-weighted imaging after carotid revascularisation: A surrogate outcome measure for procedural stroke? A systematic review and meta-analysis

2019 ◽  
Vol 4 (2) ◽  
pp. 127-143 ◽  
Author(s):  
Christopher Traenka ◽  
Stefan T Engelter ◽  
Martin M Brown ◽  
Joanna Dobson ◽  
Chris Frost ◽  
...  
Keyword(s):  
Correlation Coefficient ◽  
Diffusion Weighted Imaging ◽  
Outcome Measure ◽  
Meta Analysis ◽  
Treatment Groups ◽  
Surrogate Outcome ◽  
Relative Risks ◽  
Diffusion Weighted ◽  
Log Odds ◽  
Surrogate Outcome Measure

Aim To investigate whether lesions on diffusion-weighted imaging (DWI+) after carotid artery stenting (CAS) or endarterectomy (CEA) might provide a surrogate outcome measure for procedural stroke. Materials and Methods Systematic MedLine® database search with selection of all studies published up to the end of 2016 in which DWI scans were obtained before and within seven days after CAS or CEA. The correlation between the underlying log odds of stroke and of DWI+ across all treatment groups (i.e. CAS or CEA groups) from included studies was estimated using a bivariate random effects logistic regression model. Relative risks of DWI+ and stroke in studies comparing CAS vs. CEA were estimated using fixed-effect Mantel-Haenszel models. Results We included data of 4871 CAS and 2099 CEA procedures (85 studies). Across all treatment groups (CAS and CEA), the log odds for DWI+ was significantly associated with the log odds for clinically manifest stroke (correlation coefficient 0.61 (95% CI 0.27 to 0.87), p = 0.0012). Across all carotid artery stenting groups, the correlation coefficient was 0.19 (p = 0.074). There were too few CEA groups to reliably estimate a correlation coefficient in this subset alone. In 19 studies comparing CAS vs. CEA, the relative risks (95% confidence intervals) of DWI+ and stroke were 3.83 (3.17–4.63, p < 0.00001) and 2.38 (1.44–3.94, p = 0.0007), respectively. Discussion This systematic meta-analysis demonstrates a correlation between the occurrence of silent brain infarcts on diffusion-weighted imaging and the risk of clinically manifest stroke in carotid revascularisation procedures. Conclusion Our findings strengthen the evidence base for the use of DWI as a surrogate outcome measure for procedural stroke in carotid revascularisation procedures. Further randomised studies comparing treatment effects on DWI lesions and clinical stroke are needed to fully establish surrogacy.

Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy

2015 ◽  
Vol 25 (9) ◽  
pp. 679-685 ◽  
Author(s):  
Ulrike Bonati ◽  
Patricia Hafner ◽  
Sabine Schädelin ◽  
Maurice Schmid ◽  
Arjith Naduvilekoot Devasia ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Outcome Measure ◽  
Muscle Mri ◽  
Surrogate Outcome ◽  
Surrogate Outcome Measure

The role of MRI as a surrogate outcome measure in multiple sclerosis

2002 ◽  
Vol 8 (1_suppl) ◽  
pp. 40-51 ◽  
Author(s):  
HF McFarland ◽  
F. Barkhof ◽  
J. Antel ◽  
DH Miller
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Primary Outcome ◽  
Outcome Measure ◽  
Imaging Techniques ◽  
Primary Outcome Measure ◽  
New Therapies ◽  
Surrogate Outcome ◽  
Underlying Pathology ◽  
Surrogate Outcome Measure

The need for more specific and more sensitive outcome measures for use in testing new therapies in multiple sclerosis (MS) is generally accepted. This need has been accentuated by the realization that the ability to conduct large placebo-controlled trials will be limited in the future. From the first use of magnetic resonance imaging (MRI) to study MS, the ability of this imaging technique to identify areas of the central nervous system damage by the disease process in MS has been impressive. Thus, the possibility that MRI could serve as a surrogate outcome measure in clinical trials in MS has been attractive. The use of MRI as a surrogate outcome measure has been examined by an international group of investigators with expertise in clinical aspects of MS, the use of MRI in MS, and in experimental therapeutics. The group agreed that MRI does not represent a validated surrogate in any clinical form of MS. It was also agreed, however, that MRI does provide a reflection of the underlying pathology in the disease, but no single MRI measurement in isolation was seen as sufficient to monitor disease. The use for multiple imaging techniques, especially new, emerging techniques that may better reflect the underlying pathology, was seen as particularly important in monitoring studies of patients with either secondary or primary progressive MS. The choice of MRI techniques used to monitor new therapies needs to be consistent with the proposed mechanisms of the new therapy and phase of the disease. It was also noted, however, that additional validation is required for nonconventional imaging techniques. Finally, the participants noted that clinical trials using MRI as a primary outcome measure may fail to fully identify the effects of the therapy on clinical measures and that the risk and cost-benefit ratio of the treatment might be unresolved. Thus, before MRI is used as a primary outcome measure, new approaches to trial design must be given careful consideration. Multiple Sclerosis (2002)8, 40-51

Sign in / Sign up

Export Citation Format

Share Document